bluuebunny/crossref_metadata_2025_split huggingface dataset:
Study on the properties of polydopamine/hexadecyltrimethoxysilane co‐deposition functionalized modified graphene oxide and composite styrene–butadiene–styrene modified asphalt binder
Authors: Li Jing , Xing Susu , Lin Zibo , Zhao Zhenxia , Kong Hao , Liu Yu , Zhang Panpan 
Published: July 2023

AbstractA composite graphene oxide (GO) modifier was prepared by co‐deposition of polydopamine (PDA) and hexadecyltrimethoxysilane (HDTMS) with hydrophobic function to enhance the interfacial interaction between GO and asphalt. Dopamine as a medium enhances the adhesion of the hydrophobic functional material HDTMS on the surface of GO. And the long alkyl chains of HDTMS molecules greatly reduce the surface free energy and ensure the dispersion stability of composite GO modifier in styrene–butadiene–styrene (SBS) modified asphalt. The physical properties of modified asphalt show that the ductility, high‐temperature stability, and viscosity of asphalt can be improved by the addition of PDA/HDTMS composite GO modifiers (DH‐GO). Among them, 0.04% DH‐GO composite SBS modified asphalt binder (DH‐GO/SBSMB) has the best mechanical properties. Compared with 0.05% GO composite SBS modified asphalt binder (GO/SBSMB), the softening point of 0.04% DH‐GO/SBSMB increased by 8.3%, the penetration degree decreased by 9.7%, and the elongation increased by 18.2%. Dynamic shear rheometer (DSR), multiple stress creep recovery (MSCR) and rotational viscosity (RV) tests show that 0.04% DH‐GO/SBSMB has higher high‐temperature stability, plasticity, and viscosity than 0.05%GO/SBSMB, which meets the requirements of asphalt construction specifications.
The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease
Authors: Abhishek Abhishek , Tedeschi Sara K. , Pascart Tristan , Latourte Augustin , Dalbeth Nicola , Neogi Tuhina , Fuller Amy , Rosenthal Ann , Becce Fabio , Bardin Thomas , Ea Hang Korng , Filippou Georgios , FitzGerald John , Iagnocco AnnaMaria , Lioté Frédéric , McCarthy Geraldine M. , Ramonda Roberta , Richette Pascal , Sivera Francisca , Andres Mariano , Cipolletta Edoardo , Doherty Michael , Pascual Eliseo , Perez‐Ruiz Fernando , So Alexander , Jansen Tim L. , Kohler Minna J. , Stamp Lisa K. , Yinh Janeth , Adinolfi Antonella , Arad Uri , Aung Thanda , Benillouche Eva , Bortoluzzi Alessandra , Dau Jonathan , Maningding Ernest , Fang Meika A. , Figus Fabiana A. , Filippucci Emilio , Haslett Janine , Janssen Matthijs , Kaldas Marian , Kimoto Maryann , Leamy Kelly , Navarro Geraldine M. , Sarzi‐Puttini Piercarlo , Scirè Carlo , Silvagni Ettore , Sirotti Silvia , Stack John R. , Truong Linh , Xie Chen , Yokose Chio , Hendry Alison M. , Terkeltaub Robert , Taylor William J. , Choi Hyon K. 
Published: July 2023

ObjectiveCalcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have developed the first‐ever validated classification criteria for symptomatic CPPD disease.MethodsSupported by the ACR and EULAR, a multinational group of investigators followed established methodology to develop these disease classification criteria. The group generated lists of candidate items and refined their definitions, collected de‐identified patient profiles, evaluated strengths of associations between candidate items and CPPD disease, developed a classification criteria framework, and used multi‐criterion decision analysis to define criteria weights and a classification threshold score. The criteria were validated in an independent cohort.ResultsAmong patients with joint pain, swelling, or tenderness (entry criterion) whose symptoms are not fully explained by an alternative disease (exclusion criterion), the presence of crowned dens syndrome or calcium pyrophosphate crystals in synovial fluid are sufficient to classify a patient as having CPPD disease. In the absence of these findings, a score >56 points using weighted criteria, comprising clinical features, associated metabolic disorders, and results of laboratory and imaging investigations, can be used to classify as CPPD disease. These criteria had a sensitivity of 92.2% and specificity of 87.9% in the derivation cohort (190 CPPD cases, 148 mimickers), whereas sensitivity was 99.2% and specificity was 92.5% in the validation cohort (251 CPPD cases, 162 mimickers).ConclusionThe 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.
The developmental trajectory of functional excitation‐inhibition balance relates to language abilities in autistic and allistic children
Authors: Plueckebaum Hannah , Meyer Lars , Beck Ann‐Kathrin , Menn Katharina H. 
Published: July 2023

AbstractAutism is a neurodevelopmental condition that has been related to an overall imbalance between the brain's excitatory (E) and inhibitory (I) systems. Such an EI imbalance can lead to structural and functional cortical deviances and thus alter information processing in the brain, ultimately giving rise to autism traits. However, the developmental trajectory of EI imbalances across childhood and adolescence has not been investigated yet. Therefore, its relationship to autism traits is not well understood. In the present study, we determined a functional measure of the EI balance (f‐EIB) from resting‐state electrophysiological recordings for a final sample of 92 autistic children from 6 to 17 years of age and 100 allistic (i.e., non‐autistic) children matched by age, sex, and nonverbal‐IQ. We related the developmental trajectory of f‐EIB to behavioral assessments of autism traits as well as language ability. Our results revealed differential EI trajectories for autistic compared to allistic children. Importantly, the developmental trajectory of f‐EIB values related to individual language ability. In particular, elevated excitability in late childhood and early adolescence was linked to decreased listening comprehension. Our findings provide evidence against a general EI imbalance in autistic children when correcting for non‐verbal IQ. Instead, we show that the developmental trajectory of EI balance shares variance with autism trait development at a specific age range. This is consistent with the proposal that the late development of inhibitory brain activity is a key substrate of autism traits.
Serum metabolome profiling, network pharmacology analysis, and experimental validation of Anoectochilus roxburghii in the treatment of carbon tetrachloride–induced liver injury
Authors: Tao Yi , Yang Ying , Zhu Fei , Wu Mei , Kong Xiangjun , Wang Ping 
Published: July 2023

AbstractAnoectochilus roxburghii (Wall.) Lindl. (AR) has been traditionally used to treat inflammatory diseases, but the specific mechanism underlying its hepatoprotective effect remains unclear. Here, serum metabolomics and network pharmacology were employed to investigate the hepatoprotective mechanism of AR. Thirty male Sprague–Dawley rats were divided into six groups: normal, model, positive, high‐dose AR, middle‐dose AR, and low‐dose AR. The positive group received therapeutic doses of silibinin, whereas the AR‐treated groups received different doses of AR extract once daily. After 10 days of intragastric administration, the rats were intraperitoneally injected with a 50% CCl4 olive oil solution (2 mL/kg) to induce liver injury. Serum and liver samples were obtained, and GC–MS was utilized to monitor changes in serum metabolome. The levels of alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and hydrooxproline in serum significantly increased in the model group. On the contrary, AR‐treated group showed a significant decrease in the levels of alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and hydrooxproline. Histopathological observation also revealed that the extent of liver injury was alleviated in the AR‐treated group. Fifty differential metabolites were identified, suggesting that AR may prevent liver damage by modulating carbohydrate and amino acid metabolism.
ADT‐OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells
Authors: Xu Huangru , Li Ping , Ma Hailin , Tan Yuanhao , Wang Xiaoyang , Cai Fangfang , Xu Jiaqi , Sun Huisong , Zhuang Hongqin , Hua Zi‐Chun 
Published: July 2023

AbstractBackgroundColorectal cancer is one of the most prevalent cancers in the world, but the research on its prevention, early diagnosis and treatment is still a major challenge in clinical oncology. Thus, there is a pressing requirement to find effective strategies to improve the survival of colon cancer patients.MethodsCelecoxib has been accounted to be an effective antitumor drug, but may exhibit significant side effects. In recent studies, 5‐(4‐hydroxyphenyl)‐3H‐1,2‐dithiole‐3‐thione (ADT‐OH), one of the most commonly used reagents for the synthesis of sustained‐release H2S donors, has also been reported to inhibit cancer progression by affecting processes such as cell cycle, angiogenesis, and apoptosis. Therefore, we evaluated the therapeutic effect of the combination of ADT‐OH and celecoxib on colorectal cancer through in vitro and in vivo, hoping to achieve better therapeutic effect and reduce the effect of celecoxib on gastric injury through exogenous administration of H2S.ResultsOur results demonstrated that ADT‐OH combined with celecoxib synergistically inhibited the proliferation and migration ability of human colorectal cancer HCT116 cells, altered cell cycle and cytoskeleton, increased intracellular reactive oxygen species (ROS), and promoted cell apoptosis. Noteworthy, in vivo studies also indicated the excellent antitumor therapeutic effect of the combination therapy without apparent toxicity.ConclusionsIn general, our results provide a reasonable combination strategy of low‐dose ADT‐OH and celecoxib in the preclinical application of colorectal cancer.
Does COVID‐19 pandemic impact cancer outcomes in metastatic setting? A comparative cohort study among metastatic patients treated at day care hospital
Authors: Quilan Florian , Lequesne Justine , Cherifi François , Bastien Etienne , Morel Adeline , Delcambre Corinne , Da Silva Angélique , Grellard Jean‐Michel , Leconte Alexandra , Faveyrial Audrey , Clarisse Bénédicte , Joly Florence 
Published: July 2023

AbstractIntroductionCOVID‐19 outbreak rapidly spread since early 2020 leading to the implementation of nationwide lockdowns. To cope with this sudden change, management guidelines were quickly published to adapt oncological care, with potential impact on cancer outcomes.MethodsWe conducted a retrospective comparative cohort study to assess the impact of the COVID‐19 outbreak in 2020 on cancer outcomes in metastatic patients. Two cohorts of metastatic patients receiving intravenous (iv) therapy in a French oncological day care hospital were assessed: a 2020 cohort during the first French lockdown, and a 2018 historical cohort before the COVID‐19 pandemic. We performed a propensity score analysis to match patients from the two cohorts. After one‐year follow‐up, we compared progression‐free survival (PFS) and overall survival (OS) between cohorts. Adaptations of medical oncological treatments in 2020 were also analysed.ResultsThe 376 patients of the 2020 cohort were matched with 376 of the 2018 cohort. No SARS‐CoV‐2 infection was observed in the 2020 cohort. The adjusted PFS was significantly shorter in 2020 compared to 2018 (HR = 1.23; 95% CI: 1.03–1.46), as well as among patients without treatment adaptation compared to matched patients of the 2018 cohort (HR = 1.33; 95% CI: 1.10–1.61). We did not observe any significant difference of PFS among the group with treatment adaptations. OS was not significantly different.ConclusionMetastatic cancer patients treated during the first lockdown had a higher risk of disease progression 1 year after COVID‐19 outbreak. However, oncological treatment adaptations or SARS‐CoV‐2 infections do not explain these results. A longer follow‐up is needed to observe the impact on OS.
Transcatheter edge‐to‐edge repair for mitral regurgitation using PASCAL or MitraClip
Authors: Elbadawi Ayman , Dang Alexander T. , Hamed Mohamed , Ali Abdelrahman , Saad Marwan , Jneid Hani , Chhatriwalla Adnan K. , Goel Sachin , Bhatt Anish , Mani Preethi , Bavry Anthony , Kumbhani Dharam J. 
Published: July 2023

AbstractBackgroundThere is a paucity of data regarding the comparative efficacy and safety of Mitral valve transcatheter edge‐to‐edge repair (MTEER) using the PASCAL or MitraClip systems for patients with mitral regurgitation (MR).MethodsAn electronic search was conducted for MEDLINE, COCHRANE, and EMBASE, through February 2023, for studies comparing the clinical outcomes of MTEER using PASCAL versus MitraClip systems among patients with severe MR. The primary study outcome was residual MR ≤ 2 at discharge. Data were pooled using a random‐effects model.ResultsThe final analysis included six studies with a total of 1581 patients, with a weighted follow‐up period of 3.5 months. Two studies only included patients with degenerative MR, while the remaining studies included both degenerative and functional MR. There was no significant difference in procedure duration between MTEER with the PASCAL or MitraClip systems. There was no difference in residual MR ≤ 2 at discharge (94.7% vs. 91.9%; odds ratio [OR]: 1.44; 95% confidence interval [CI]: 0.92–2.27) or residual MR ≤ 2 at the mid‐term follow‐up (94.6% vs. 91.0%, p = 0.05) among the PASCAL versus MitraClip systems. There was no difference between both groups in residual MR ≤ 1 at discharge (73.1% vs. 63.8%, p = 0.12), while there was greater incidence of residual MR ≤ 1 at midterm follow‐up with the PASCAL system (71.3% vs. 56.2%, p < 0.001). There was no difference between the PASCAL and MitraClip MTEER systems in technical success (97.0% vs. 97.9%, p = 0.15), procedural success (89.1% vs. 87.1%, p = 0.78), single leaflet detachment (1.8% vs. 1.4%, p = 0.55), or all‐cause mortality (3.6% vs. 4.6%, p = 0.71).ConclusionIn this meta‐analysis, we demonstrated comparable efficacy and safety between the PASCAL and MitraClip MTEER systems at short‐ and mid‐term assessments. Randomized trials are warranted to evaluate the comparative long‐term outcomes between both MTEER systems.
Ultrathin bioresorbable polymer sirolimus‐eluting stents in US patients undergoing coronary revascularization: 1‐Year outcomes from the BIOFLOW VII trial
Authors: Kandzari David E. , Garcia‐Garcia Hector M. , Stoler Robert C. , Wang John , Picone Mark , Ben‐Dor Itsik , Garcia Santiago A. 
Published: July 2023

AbstractBackgroundUltrathin strut coronary drug‐eluting stents (DES) have demonstrated improved safety and efficacy in large contemporary trials. The evaluation of an ultrathin strut DES in a post‐market United States (US) patient population was undertaken.ObjectiveThe purpose of this post‐approval study is to confirm that the clinical performance of an ultrathin strut bioresorbable polymer sirolimus‐eluting stent (BP SES) in clinical practice is similar to that observed with BP SES in the BIOFLOW V pivotal trial.MethodsBIOFLOW VII is a prospective, multicenter, single‐arm US post‐market approval study to confirm the clinical performance of BP SES in a real‐world setting. The primary endpoint of 1‐year target lesion failure (TLF) was compared with a performance goal of 6.9% based on an adapted BIOFLOW V trial BP SES TLF rate and TLF rates from other US market‐released DES utilizing the Society for Cardiovascular Angiography and Interventions definition for peri‐procedural myocardial infarction (MI). Subjects undergoing percutaneous coronary intervention with BP SES were consented within 24 h post‐index procedure with planned follow‐up through 5 years.ResultsAmong 556 enrolled patients, clinical demographics included: 34.7% female, 35.6% with diabetes mellitus, and 56.8% with acute coronary syndromes. The average stent length (mean ± standard deviation) was 20.2 ± 11.8 mm, and the mean number of stents per patient was 1.3 ± 0.6. Procedure success was 99.1% (551/556), and device success was 99.9% (689/690). Among 531 subjects included in the primary endpoint analysis, the 1‐year rate of TLF rate was 1.7% (9/531), and the primary endpoint was met compared with the performance goal (p < 0.0001, 95% confidence interval: 0.69%, 3.43%). Rates of target vessel MI and clinically driven target lesion revascularization were 1.3% (7/531) and 0.9% (5/531), with no occurrence of cardiac death. Definite stent thrombosis was observed for two cases (0.4%; 2/556) with one acute (≤24 h) and one late (>30 days and ≤1 year) event.ConclusionIn a post‐approval study, 1‐year clinical outcomes with BP SES were consistent with prior trials supporting the safety and effectiveness of ultrathin BP SES.
Prognostic impact of new permanent pacemaker implantation following transcatheter aortic valve replacement
Authors: Zheng Hua‐Jie , Yan Chao‐Jun , Lin De‐Qing , Cheng Yong‐Bo , Yu San‐Jiu , Li Jun , Zhang Xian‐Pu , Cheng Wei 
Published: July 2023

AbstractBackgroundConduction disturbances requiring permanent pacemaker implantation (PPI) are common following transcatheter aortic valve replacement (TAVR). There were conflicting data regarding the impact of new PPI on clinical outcomes after TAVR.ObjectivesThe study sought to evaluate the impact of new PPI on clinical outcomes in patients undergoing TAVR.MethodsThis study was a retrospective analysis of prospectively collected data. Data were from 210 consecutive patients without prior PPI who underwent TAVR due to severe symptomatic aortic stenosis at our center between June 2018 and July 2020. Clinical, echocardiographic, and pacing data were assessed at 30‐day, 1‐ and 2‐year follow‐up.ResultsNew PPI was required in 35 (16.7%) patients within 30 days after TAVR. The median time from TAVR to PPI was 3 days. The most common indication for PPI was high‐degree or complete atrioventricular block. The median follow‐up was 798.0 (interquartile range, 669.0–1115.0) days. There were no differences in all‐cause mortality (adjusted hazard ratio [HR]: 1.18; 95% confidence interval [CI]: 0.85–2.36; p = 0.415) and cardiovascular mortality (adjusted HR: 0.92; 95% CI: 0.57–1.89; p = 0.609) between groups. However, PPI group had a higher risk of heart failure (HF) rehospitalization (adjusted HR: 1.53; 95% CI: 1.26–2.28; p = 0.027). Echocardiography showed no significant improvement of LVEF over time in patients with PPI. At the latest follow‐up, 31.3% of patients exhibited low (≤10%) pacing burdens, whereas 28.1% of patients had near constant (>90%) right ventricular pacing.ConclusionsNew PPI within 30 days following TAVR was not associated with an increased risk of all‐cause or cardiovascular mortality. However, patients with PPI had a higher risk of HF rehospitalization and lack of LVEF improvement.
Modeling Reactivity of Nitrite and Nitrous Acid at a Phenolate Bridged Dizinc(II) Site: Insights into NO Signaling at Zinc
Authors: Kolliyedath Gayathri , Chattopadhyay Taraknath , Mondal Aditesh , Panangattu Aiswarya , Muralikrishnan Girish , Kundu Subrata 
Published: July 2023

AbstractAlthough nitrite‐to‐NO transformation at various transition metals including Fe and Cu are relatively well explored, examples of such a reaction at the redox‐inactive zinc(II) site are limited. The present report aims to gain insights into the reactivity of nitrite anions, nitrous acid (HONO), and organonitrite (RONO) at a dizinc(II) site. A phenolate‐bridged dizinc(II)‐aqua complex [LHZnII(OH2)]2(ClO4)2 (1H‐Aq, where LH=tridentate N,N,O‐donor monoanionic ligand) is illustrated to react with tBuONO to provide a metastable arene‐nitrosonium charge‐transfer complex 2H. UV‐vis, FTIR, multinuclear NMR, and elemental analyses suggests the presence of a 2 : 1 arene‐nitrosonium moiety. Furthermore, the reactivity of a structurally characterized zinc(II)‐nitrite complex [LHZnII(ONO)]2 (1H‐ONO) with a proton‐source demonstrates HONO reactivity at the dizinc(II) site. Reactivity of both RONO (R=alkyl/H) at the phenolate‐bridged dizinc(II) site provides NO+ charge‐transfer complex 2H. Subsequently, the reactions of 2H with exogenous reductants (such as ferrocene, thiol, phenol, and catechol) have been illustrated to generate NO. In addition, NO yielding reactivity of [LHZnII(ONO)]2 (1H‐ONO) in the presence of the above‐mentioned reductants have been compared with the reactions of complex 2H. Thus, this report sheds light on the transformations of NO2−/RONO (R=alkyl/H) to NO/NO+ at the redox‐inactive zinc(II) coordination motif.
Donor‐Acceptor Activation of Carbon Dioxide
Authors: Pérez‐Jiménez Marina , Corona Helena , de la Cruz‐Martínez Felipe , Campos Jesús 
Published: July 2023

AbstractThe activation and functionalization of carbon dioxide entails great interest related to its abundance, low toxicity and associated environmental problems. However, the inertness of CO2 has posed a challenge towards its efficient conversion to added‐value products. In this review we discuss one of the strategies that have been widely used to capture and activate carbon dioxide, namely the use of donor‐acceptor interactions by partnering a Lewis acidic and a Lewis basic fragment. This type of CO2 activation resembles that found in metalloenzymes, whose outstanding performance in catalytically transforming carbon dioxide encourages further bioinspired research. We have divided this review into three general sections based on the nature of the active sites: metal‐free examples (mainly formed by frustrated Lewis pairs), main group‐transition metal combinations, and transition metal heterobimetallic complexes. Overall, we discuss one hundred compounds that cooperatively activate carbon dioxide by donor‐acceptor interactions, revealing a wide range of structural motifs.
Mini‐Review: Progress on the Controllable Synthesis of Micro/Nanoscale Bi2S3 Functional Materials
Authors: Yang Chen , Zhao Yijing , Liu Pengchao , Wang Didi , Sun Yan , Li Chunsheng , Dong Yongping , Ye Mingfu , Zhang Ning , Zhu Zhu , Jiang Huidong , Zhu Jiahao , Shuai Miaoxi , Wei Tonghui , Zhao Yuzhen 
Published: July 2023

AbstractBismuth sulfide (Bi2S3) with micro/nanostructures as an important semiconductor material has attracted considerable attention due to its high ionic conductance, high photoelectric conversion efficiency, and large absorption coefficient, which is widely applied in the areas of photocatalysis, energy conversion, sensors, biomedicine, and pollutant disposal. Up to now, various strategies are reported for the morphology‐controlled synthesis of micro‐nanoscale Bi2S3 and Bi2S3‐based materials via manipulating the thermodynamics and kinetics in the chemical fabricating process. However, the Bi2S3 with designed shapes still remains to be developed to well adapt these diverse usages. To conclude, the designed preparation strategies, advanced applications, current challenges, and future expectations of Bi2S3 are discussed to provide some potential suggestions for further promotion of Bi2S3 functional materials.